Investment House LLC Buys 6,043 Shares of Edwards Lifesciences Co. (NYSE:EW)

Investment House LLC boosted its stake in shares of Edwards Lifesciences Co. (NYSE:EW) by 4.0% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 156,263 shares of the medical research company’s stock after buying an additional 6,043 shares during the quarter. Investment House LLC’s holdings in Edwards Lifesciences were worth $11,915,000 as of its most recent SEC filing.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Nordea Investment Management AB raised its holdings in shares of Edwards Lifesciences by 1,224.1% in the 4th quarter. Nordea Investment Management AB now owns 1,610,412 shares of the medical research company’s stock valued at $123,261,000 after purchasing an additional 1,488,791 shares in the last quarter. Telos Capital Management Inc. grew its position in shares of Edwards Lifesciences by 158.2% in the 4th quarter. Telos Capital Management Inc. now owns 91,405 shares of the medical research company’s stock worth $6,970,000 after buying an additional 56,000 shares during the last quarter. Arlington Trust Co LLC grew its position in shares of Edwards Lifesciences by 5,092.4% in the 4th quarter. Arlington Trust Co LLC now owns 12,306 shares of the medical research company’s stock worth $938,000 after buying an additional 12,069 shares during the last quarter. Versor Investments LP grew its position in shares of Edwards Lifesciences by 83.3% in the 3rd quarter. Versor Investments LP now owns 4,496 shares of the medical research company’s stock worth $311,000 after buying an additional 2,043 shares during the last quarter. Finally, HealthInvest Partners AB purchased a new position in shares of Edwards Lifesciences in the 4th quarter worth approximately $1,587,000. Institutional investors own 79.46% of the company’s stock.

Analysts Set New Price Targets

A number of analysts have recently weighed in on the stock. StockNews.com lowered shares of Edwards Lifesciences from a “buy” rating to a “hold” rating in a research note on Wednesday, March 20th. Bank of America upgraded shares of Edwards Lifesciences from a “neutral” rating to a “buy” rating in a research report on Thursday, March 7th. Oppenheimer raised their price target on shares of Edwards Lifesciences from $93.00 to $100.00 and gave the company an “outperform” rating in a research report on Monday, March 18th. Evercore ISI dropped their price target on shares of Edwards Lifesciences from $92.00 to $89.00 and set an “in-line” rating on the stock in a research report on Friday. Finally, OTR Global upgraded shares of Edwards Lifesciences from a “mixed” rating to a “positive” rating in a research report on Tuesday, March 26th. One equities research analyst has rated the stock with a sell rating, seven have given a hold rating and ten have assigned a buy rating to the stock. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $92.71.

Edwards Lifesciences Stock Performance

Edwards Lifesciences stock traded down $0.41 during mid-day trading on Monday, reaching $86.02. The company’s stock had a trading volume of 1,458,816 shares, compared to its average volume of 3,814,264. The firm has a market cap of $51.78 billion, a price-to-earnings ratio of 37.25, a PEG ratio of 4.28 and a beta of 1.05. The business has a 50 day moving average price of $90.28 and a 200-day moving average price of $78.95. The company has a current ratio of 3.75, a quick ratio of 2.67 and a debt-to-equity ratio of 0.08. Edwards Lifesciences Co. has a twelve month low of $60.57 and a twelve month high of $96.12.

Edwards Lifesciences (NYSE:EW) last posted its earnings results on Thursday, April 25th. The medical research company reported $0.66 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.64 by $0.02. Edwards Lifesciences had a return on equity of 22.86% and a net margin of 23.01%. The company had revenue of $1.60 billion for the quarter, compared to analysts’ expectations of $1.58 billion. Sell-side analysts predict that Edwards Lifesciences Co. will post 2.76 EPS for the current fiscal year.

Insider Activity at Edwards Lifesciences

In other Edwards Lifesciences news, VP Daniel J. Lippis sold 1,715 shares of the business’s stock in a transaction dated Thursday, March 7th. The shares were sold at an average price of $90.98, for a total value of $156,030.70. Following the sale, the vice president now directly owns 17,213 shares in the company, valued at $1,566,038.74. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. In related news, Director Michael A. Mussallem sold 29,350 shares of Edwards Lifesciences stock in a transaction dated Monday, March 4th. The stock was sold at an average price of $86.67, for a total value of $2,543,764.50. Following the transaction, the director now owns 4,486 shares of the company’s stock, valued at approximately $388,801.62. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, VP Daniel J. Lippis sold 1,715 shares of Edwards Lifesciences stock in a transaction dated Thursday, March 7th. The stock was sold at an average price of $90.98, for a total value of $156,030.70. Following the completion of the transaction, the vice president now directly owns 17,213 shares in the company, valued at approximately $1,566,038.74. The disclosure for this sale can be found here. Insiders have sold a total of 194,004 shares of company stock worth $17,166,254 over the last ninety days. 1.27% of the stock is currently owned by corporate insiders.

Edwards Lifesciences Company Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.